A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF VIMSELTINIB TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (MOTION)

Registry ID

DCC-3014-03-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

DECIPHERA PHARMACEUTICALS. LLC

Start date

2021-10-15

Last update

2021-04-23

Conditions

• GIANT CELL TUMORS

Related clinical trials

• A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY AND EFFICACY OF EMACTUZUMAB VS. PLACEBO IN SUBJECTS WITH TENOSYNOVIAL GIANT CELL TUMOUR
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ABSK021 TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

View on source registry